<DOC>
	<DOCNO>NCT01256671</DOCNO>
	<brief_summary>The purpose Phase III trial ass long-term safety intravaginal dehydroepiandrosterone ( DHEA ) non-hysterectomized postmenopausal woman vaginal atrophy age 40 75 year .</brief_summary>
	<brief_title>DHEA Against Vaginal Atrophy - Safety Study 12 Months</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Main Postmenopausal woman ( nonhysterectomized ) Women 40 75 year age . Willing participate study sign inform consent . Women selfidentified symptom ( ) vaginal atrophy . Willing endometrial biopsy screen end study ( Week 52 ) . Main Undiagnosed abnormal genital bleeding . Hypertension equal 140/90 mm Hg . The administration investigational drug within 30 day screen visit . Endometrial hyperplasia , cancer endometrial histology show proliferative , secretory menstrual type characteristic histologic evaluation endometrial biopsy perform screening .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Vulvar/Vaginal Atrophy</keyword>
	<keyword>Atrophic Vaginitis</keyword>
	<keyword>Dehydroepiandrosterone</keyword>
	<keyword>DHEA</keyword>
	<keyword>Prasterone</keyword>
	<keyword>Vaginorm</keyword>
	<keyword>Menopause</keyword>
</DOC>